Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine

Abstract In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 a...

Descripció completa

Dades bibliogràfiques

Autors principals:	Holly Janes, Youyi Fong, Ying Huang, David Benkeser, Elizabeth J. Kelly, Ian Hirsch, Ann Marie Stanley, Tonya Villafana, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Ann R. Falsey, Magdalena E. Sobieszczyk, Richard A. Koup, Peter B. Gilbert, On behalf of the AstraZeneca AZD1222 Clinical Study Group, The Immune Assays Team, The United States Government (USG)/CoVPN Biostatistics Team
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-04-01
Col·lecció:	npj Vaccines
Accés en línia:	https://doi.org/10.1038/s41541-026-01411-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!